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Background: HIV and TB are common infections in sub-Saharan Africa. Due to HIV’s suppression of 
the immune system, infected patients are prone to opportunistic infections. Co-treatment of HIV and 
TB places patients at risk of adverse drug reactions (ADRs) and drug interactions. This study aimed 
to determine the incidence and risk factors for ADRs in HIV-infected patients and those co-infected 
with TB.  Methods: Data from patients (aged >15 years) enrolled on the Medunsa National 
Pharmacovigilance Centre’s database from March 2007 to May 2017 were analysed. Censoring 
targeted the first incident of ADRs in HIV-TB co-infected patients and those not co-infected. A Cox-
proportional hazard model was used to determine associations of dependant variables and identify 
predictors for developing ADRs.  Results: 3608 HIV-infected patients were included. 12% (n=437) 
had HIV-TB co-infection. Overall prevalence of ADRs was 31% (n=1 131). Of these, 12% were 
experienced by patients with HIV and TB co-infection and 885 by patients with no co-infection. Higher 
rates of ADRs were found to be significantly associated with patients initiated on stavudine (aHR=9.4; 
95% CI 7.4-12.1; p<0.001) and non-standardised regimens (aHR=6.6; 95% CI 4.5-9.8; p<0.001). 
Peripheral neuropathy and skin rash were the most common ADRs. Patients initiated on a CD4+ 
count <350 cells/mm3 (aHR=1.3; 95% CI 1.1-1.4, p<0.001) and cigarette smokers (aHR=1.4; 95% CI 
1.1-1.7, p=0.015) were at higher risk of developing ADRs.  Conclusion: Overall, results suggested a 
modest incidence of ADRs amongst HIV- and TB co-infected, with no significant association between 
ADRs and TB-coinfection. A pharmacovigilance surveillance system remains essential. 
 
